ARTICLE | Clinical News
514G3 regulatory update
October 12, 2015 7:00 AM UTC
FDA granted Fast Track designation to 514G3 from XBiotech to treat Staphylococcus aureus infections. The mAb against S. aureus is based on True Human technology and is in Phase I/II testing for the in...